A Phase 1/2 interventional study of QL1706 (bispecific antibody targeting PD-1 and CLTA-4) and Pemetrexed (Alimta) in Leptomeningeal Metastasis, Pemetrexed and PD-1 Inhibitor, sponsored by Guangzhou Medical University. Active, not recruiting at 5 sites in China. Open to participants aged 21 Years to 75 Years. Per ClinicalTrials.gov, last updated 2026-10-13.
Sponsored by Guangzhou Medical University · Phase 1/2, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 54 studies in Meningeal Carcinomatosis with a site in China — 29 open to participants now, 34 under way, none of them phase 3. Meningeal Carcinomatosis · China.
Among the 54 studies in Meningeal Carcinomatosis with a site in China, this one is the 23rd largest by planned enrollment of the 46 interventional ones that give a count, is one of 11 that started in 2025, is one of 8 in phase 1/2, reaches primary completion later than 12 of the 33 other live ones, and was the 39th registered.
146 studies on the registry are indexed under Meningeal Carcinomatosis; 48 are open to participants now.
Browse Meningeal Carcinomatosis studies →29 of the 54 studies in Meningeal Carcinomatosis with a site in China are open now. Recruiting first, the newest first:
Guangzhou University of Traditional Chinese Medicine · Sites in China
Ages 18–75
Second Affiliated Hospital of Nanchang University · Sites in China
Ages 18–99
Alpha Biopharma (Jiangsu) Co., Ltd. · Sites in China
Ages 18+
Guangzhou Medical University · Sites in China
Ages 18–75
Tianjin Medical University Cancer Institute and Hospital · Sites in China
Ages 18–75
A study can be open while its sites in China have not opened yet or have stopped. Only those recruiting at a site in China →
Of the 33 Meningeal Carcinomatosis studies recruiting now, 21 (64%) set no upper age limit and 10 (30%) stop at 75 or younger; 1 takes children under 18; none take healthy volunteers.
This study: 21 Years to 75 Years · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
54 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 14 · Phase 2 27 · Phase 4 3
First in 2011; this study’s year is marked. 11 started in 2025.
By drug class, each counting the studies that test any of its medicines:
This study's planned enrollment of 39 is above the median of 30 across 128 interventional studies indexed under Meningeal Carcinomatosis.
Median enrollment 39 across the 46 interventional studies, 86 across the 8 observational. Of the 11 that completed or were terminated, 0 (0%) have results posted.
This tab as a report to print or save as PDF → With an account.
2 of 54 have an industry lead sponsor. The 10 most frequent:
Guangzhou Medical University is the lead sponsor of 40 studies on the registry; 22 are open to participants now.
Guangzhou Medical University has 8 studies filed under Meningeal Carcinomatosis — fewer than ten, so there is no comparison to draw.
10 of the studies in Meningeal Carcinomatosis with a site in China that are under way reach primary completion within a year, 0 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT06462222Guangzhou Medical UniversityImmune Checkpoint Inhibitor Combined With Pemetrexed Intrathecal Injection for Leptomeningeal Metastasis From Solid Tumors | 2026-11 |
| NCT06809530Guangzhou Medical UniversityIntrathecal Dual Checkpoint Inhibitor (PD-1 and CTLA-4) in Combination With Pemetrexed for Leptomeningeal Metastasis | 2026-12-01 |
| NCT06462092Guangzhou Medical UniversitySacituzumab Govitecan and Intrathecal Chemotherapy for Treating Leptomeningeal Metastases From Her2-negative Breast Cancer | 2027-01-15 |
| NCT07193654Second Affiliated Hospital, School of Medicine, Zhejiang UniversityStupp Treatment With Intrathecal Injection of Thiotepa for Glioblastoma With Advanced Spread | 2027-04-01 |
| NCT07092202Union Hospital, Tongji Medical College, Huazhong University of Science and TechnologyFirmonertinib Combined With Intrathecal Injection for the Treatment of EGFR Mutant NSCLC With Leptomeningeal Metastases | 2027-05-01 |
Add all 10 to your calendar (.ics) → With an account.
Among the 54 studies in Meningeal Carcinomatosis with a site in China, from their registry updates:
This tab as a report to print or save as PDF → With an account.
This phase I/II study is to evaluate the recommended dose, safety, feasibility, and therapeutic response of intrathecal dual checkpoint inhibitor (targeting PD-1 and CTLA-4 with QL1706) in combination with pemetrexed in patients with leptomeningeal metastasis.
This study is a prospective, single-arm, phase I/II clinical trial evaluating intrathecal dual checkpoint inhibitor (targeting PD-1 and CTLA-4 with the bispecific antibody QL1706) in combination with pemetrexed for the treatment of leptomeningeal metastasis.
Intrathecal pemetrexed is administered twice weekly for 2 weeks (induction phase), then weekly for 4 weeks (consolidation phase), and monthly thereafter (maintenance phase). Intrathecal QL1706 (a co-formulation of separate anti-PD-1 and anti-CTLA-4 antibodies) is given every two weeks during the six-week (induction and consolidation phase), followed by monthly injections in the maintenance phase, until disease progression or death.
The primary objectives are to determine the recommended dose of intrathecal QL1706 in combination with pemetrexed and to assess safety based on the incidence of treatment-related adverse events. Clinical response rate, disease control rate, and overall survival are also evaluated. Patients undergo cerebrospinal fluid and blood specimen collection to evaluate potential clinical, molecular, and/or immune predictors of treatment efficacy and safety.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
The diagnosis was confirmed by looking at a sample under a microscope: tissue from a biopsy or surgery (histology), or cells from a fluid or needle sample (cytology).
Your pathology report is the document that shows this.
The human immunodeficiency virus, which weakens the immune system.
Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.
Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.
Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.
A condition in which the immune system attacks the body’s own tissues, such as rheumatoid arthritis, lupus, psoriasis, type 1 diabetes or inflammatory bowel disease.
Immunotherapy studies often leave out active autoimmune disease, and some name exceptions, such as thyroid disease on replacement hormone. Check the exceptions this study lists.
Histologically or cytologically confirmed
The diagnosis was confirmed by looking at a sample under a microscope: tissue from a biopsy or surgery (histology), or cells from a fluid or needle sample (cytology).
Your pathology report is the document that shows this.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
HIV
The human immunodeficiency virus, which weakens the immune system.
Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Hepatitis B tests
Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.
Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Autoimmune disease
A condition in which the immune system attacks the body’s own tissues, such as rheumatoid arthritis, lupus, psoriasis, type 1 diabetes or inflammatory bowel disease.
Immunotherapy studies often leave out active autoimmune disease, and some name exceptions, such as thyroid disease on replacement hormone. Check the exceptions this study lists.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
This study is a prospective, single-arm, Phase I/II clinical trial. The primary objectives were to determine the recommended dose of intrathecal dual checkpoint inhibitor (PD-1 and CTLA-4, QL1706) in combination with pemetrexed and safety based on the incidence of treatment-related adverse events. Clinical response rate (CRR), disease control rate (DCR) and overall survival (OS) are also evaluated. Patients will have cerebrospinal fluid (CSF) and blood specimen collection for the evaluation of predictors (clinical, molecular, and/or immune) of the efficacy and safety of this regimen.
Drug: QL1706 (bispecific antibody targeting PD-1 and CLTA-4) · Drug: Pemetrexed (Alimta)
Drug page: Iparomlimab/TuvonralimabStudies of Iparomlimab/TuvonralimabIparomlimab/Tuvonralimab pageHow we knowJudged by ClinicalTrials.gg, not part of the registry record.
Intrathecal injection of PD-1/CTLA-4 bispecific antibody was administered every 2 weeks for 6 weeks during the induction phase, followed by monthly injections during the maintenance phase, until recurrence or death.
Pemetrexed (Alimta, Eli Lilly and Company) was administrated by intrathecal injection, first as induction therapy, twice per week for 2 weeks, followed by consolidation therapy, once per week for 4 weeks, then maintenance therapy, once per month until the patient's death, leptomeningeal metastasis progresses, or intolerable severe adverse events occurred.
RP2D
The recommended phase II dose. The dose limiting toxicity was defined as ≥ grade 3 neurological toxicities (e.g.,meningitis) or other grade 4 toxicity.
Time frame: Dose limiting toxicity was assessed during the first 6 weeks after the first intrathecal administration.
Incidence of treatment-related adverse events
The incidence of treatment-related adverse events were measured for determining tolerability and safety. Adverse events (AEs) are evaluated according to the Common Terminology Criteria for Adverse Events (CTCAE). Events of grade 3-5 are defined as moderate and severe adverse events.
Time frame: From date of treatment until the date of first documented progression or date of death from any cause, whichever came first, assessed up to 6 months.
Clinical response rate
The response assessment in neuro-oncology criteria (RANO) proposal for response criteria of leptomeningeal metastasis was used to assess the clinical response in this study.
Time frame: From date of treatment until the date of first documented progression or date of death from any cause, whichever came first, assessed up to 6 months
Disease control rate (DCR)
Disease control rate was defined as proportion of patients achieving clinical response or stable disease. Clinical response and stable disease were determined based on the RANO proposal evaluation criteria which have been established and published on Neuro Oncol.
Time frame: From date of treatment until the date of first documented progression or date of death from any cause, whichever came first, assessed up to 6 months.
Overall survival(OS)
Overall survival was recorded since the date of patient enrollment. All patients were followed up until death or the end of the study.
Time frame: From the enrollment of this study until date of death from any cause, whichever came first, or the last follow-up, assessed up to 6 months.
Plan to share: No
No publications or documents are linked to this record.
Started Mar 2025 (actual). Primary completion is estimated for Dec 2026, 20 months after the start.
How these figures are worked out, and which studies are left out of them.
From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗
This study is active, not recruiting, as verified in Jul 2026. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drug tested here: Iparomlimab/Tuvonralimab
Guangzhou Medical University